OrbiMed Advisors LLC, along with OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, has made a substantial investment of $15 million in Q32 Bio Inc. (NASDAQ:QTTB), acquiring 1,875,000 shares at a price of $8.00 each on May 28, 2026. Since the acquisition, the stock has appreciated by 46%, currently trading at $11.66. This investment reflects OrbiMed's significant stake in Q32 Bio, where it holds a total of 3,502,987 shares through its investment vehicles. Q32 Bio has reported an impressive 537% return over the past year and boasts a 'GREAT' financial health score according to InvestingPro. Additionally, the company has announced a $55 million private placement financing, selling around 6.9 million shares at $8 per share. Analysts from Mizuho and H.C. Wainwright have issued positive ratings, with price targets set at $14.00 and $13.00, respectively, indicating confidence in the potential of Q32 Bio's lead program, bempikibart, for treating alopecia areata. These developments highlight Q32 Bio's active financial strategies as it progresses with its programs.